Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934568 · ClinicalTrials.gov registry record · Phase 2
Ribociclib (LEE011) Rollover Study for Continued Access
A Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 13
- Study locations
NCT02934568 is a Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 22 participants. The trial reports 13 study locations across 7 states.
The verdict
NCT02934568, a Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Conditions Studied
Interventions
- DRUG LEE011
Study Locations (13)
Other
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Tainan
- Novartis Investigative Site - Taipei
Alabama
- University Of Alabama At Birmingham - Birmingham
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- The Regents of the Uni of Michigan - Ann Arbor
New York
- Broome Oncology - Johnson City
Tennessee
- St Jude Childrens Research Hospital - Memphis
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02934568
The ClinicalTrials.gov registry entry for NCT02934568 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which LEE011 is the first listed.
NCT02934568 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02934568 about?
NCT02934568 is a clinical study titled "Ribociclib (LEE011) Rollover Study for Continued Access". This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for othe...
What is the current status of trial NCT02934568?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-12-15. Estimated completion is 2027-02-01.
What conditions does trial NCT02934568 study?
This clinical trial studies the following conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies.
What interventions are being tested in trial NCT02934568?
The interventions under investigation include: LEE011 (DRUG).
Who is sponsoring clinical trial NCT02934568?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02934568 being conducted?
This trial has 13 study locations across Alabama, Massachusetts, Michigan, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.